{Reference Type}: Journal Article
{Title}: Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients.
{Author}: Cheng X;Li YN;Fan YB;Zhao HH;Li L;Lu C;Zhu LH;Niu Q;
{Journal}: Clin Neurol Neurosurg
{Volume}: 244
{Issue}: 0
{Year}: 2024 Sep 19
{Factor}: 1.885
{DOI}: 10.1016/j.clineuro.2024.108462
{Abstract}: <B>OBJECTIVE: </B>Recent studies have suggested that neuroinflammation may play a role in the progression of spinal muscular atrophy (SMA), and this may influence the efficacy of antisense oligonucleotide treatment. This study explored the biomarkers associated with SMA and the efficacy of nusinersen therapy.<BR><B>METHODS: </B>Fifteen patients with SMA were enrolled and their motor function (World Health Organization motor milestone, Hammersmith Functional Motor Scale Expanded (HFMSE), and Revised Upper Limb Module [RULM] scores, and 6-minute walking test) was evaluated before, during (63 days), and after (6 months) nusinersen treatment. The concentrations of monocyte chemoactive protein 1 (MCP1), tumour necrosis factor-alpha (TNF-α), and interleukin (IL)-10 in the cerebrospinal fluid were measured at the indicated time points, and their correlations with motor function were analysed.<BR><B>RESULTS: </B>A significant increase in MCP1 was observed after 6 month's treatment compared with that before treatment, while TNF-α gradually decreased over the course of treatment. IL-10 levels were negatively correlated with HFMSE scores before treatment, and reductions in IL-10 levels were correlated with improvements in RULM scores.<BR><B>CONCLUSIONS: </B>This study suggests that neuroinflammation may be associated with the severity of SMA and with the therapeutic effects of nusinersen, which could have clinical implications in the treatment of SMA.